TheClinic by Anca Pralea ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  3.6% 3.6% 3.6% 3.6% 3.6%  
Bankruptcy risk  20.0% 15.5% 18.4% 17.7% 17.0%  
Credit score (0-100)  6 12 7 8 9  
Credit rating  B BB B B BB  
Credit limit (kDKK)  -0.0 -0.0 -0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  -10.0 -1.0 -26.0 99.0 -4.6  
EBITDA  -10.0 -1.0 -26.0 99.0 -4.6  
EBIT  -10.0 -1.0 -26.0 99.0 -4.6  
Pre-tax profit (PTP)  -10.0 -1.0 -27.0 99.0 -5.2  
Net earnings  -10.0 -1.0 -27.0 86.0 -5.0  
Pre-tax profit without non-rec. items  -10.0 -1.0 -27.0 99.0 -5.2  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  -9.0 -10.0 2.0 53.0 35.8  
Interest-bearing liabilities  63.0 67.0 39.0 0.0 5.1  
Balance sheet total (assets)  59.0 62.0 47.0 124 45.4  

Net Debt  50.0 59.0 32.0 -95.0 -17.3  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -10.0 -1.0 -26.0 99.0 -4.6  
Gross profit growth  0.0% 90.0% -2,500.0% 0.0% 0.0%  
Employees  0 0 0 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  59 62 47 124 45  
Balance sheet change%  0.0% 5.1% -24.2% 163.8% -63.4%  
Added value  -10.0 -1.0 -26.0 99.0 -4.6  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 -2.0 -3.0 1.0 -1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -14.7% -1.4% -43.7% 115.8% -5.5%  
ROI %  -15.9% -1.5% -48.1% 210.6% -9.9%  
ROE %  -16.9% -1.7% -84.4% 312.7% -11.3%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  -13.2% -13.9% 4.3% 42.7% 78.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -500.0% -5,900.0% -123.1% -96.0% 373.2%  
Gearing %  -700.0% -670.0% 1,950.0% 0.0% 14.2%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 1.9% 0.0% 23.3%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  2.4 1.4 1.2 1.3 2.4  
Current Ratio  11.8 12.4 7.8 1.7 4.7  
Cash and cash equivalent  13.0 8.0 7.0 95.0 22.4  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  54.0 57.0 41.0 53.0 35.8  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 99 -5  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 99 -5  
EBIT / employee  0 0 0 99 -5  
Net earnings / employee  0 0 0 86 -5